<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4">
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">Genome Res</journal-id>
        <journal-id journal-id-type="iso-abbrev">Genome Res</journal-id>
        <journal-id journal-id-type="pmc-domain-id">102</journal-id>
        <journal-id journal-id-type="pmc-domain">genores</journal-id>
        <journal-id journal-id-type="publisher-id">GENOME</journal-id>
        <journal-title-group>
          <journal-title>Genome Research</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">1088-9051</issn>
        <issn pub-type="epub">1549-5469</issn>
        <publisher>
          <publisher-name>Cold Spring Harbor Laboratory Press</publisher-name>
        </publisher>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC5378171</article-id>
        <article-id pub-id-type="pmcid-ver">PMC5378171.1</article-id>
        <article-id pub-id-type="pmcaid">5378171</article-id>
        <article-id pub-id-type="pmcaiid">5378171</article-id>
        <article-id pub-id-type="pmid">28373299</article-id>
        <article-id pub-id-type="doi">10.1101/gr.213348.116</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Research</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Integrated genomic analyses reveal frequent <italic toggle="yes">TERT</italic> aberrations in acral melanoma</article-title>
          <alt-title alt-title-type="left-running">Liang et al.</alt-title>
          <alt-title alt-title-type="right-running">Genomic analysis of acral melanoma</alt-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Liang</surname>
              <given-names initials="WS">Winnie S.</given-names>
            </name>
            <xref ref-type="aff" rid="af1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Hendricks</surname>
              <given-names initials="W">William</given-names>
            </name>
            <xref ref-type="aff" rid="af1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Kiefer</surname>
              <given-names initials="J">Jeffrey</given-names>
            </name>
            <xref ref-type="aff" rid="af1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Schmidt</surname>
              <given-names initials="J">Jessica</given-names>
            </name>
            <xref ref-type="aff" rid="af2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Sekar</surname>
              <given-names initials="S">Shobana</given-names>
            </name>
            <xref ref-type="aff" rid="af1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Carpten</surname>
              <given-names initials="J">John</given-names>
            </name>
            <xref ref-type="aff" rid="af1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Craig</surname>
              <given-names initials="DW">David W.</given-names>
            </name>
            <xref ref-type="aff" rid="af1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Adkins</surname>
              <given-names initials="J">Jonathan</given-names>
            </name>
            <xref ref-type="aff" rid="af1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Cuyugan</surname>
              <given-names initials="L">Lori</given-names>
            </name>
            <xref ref-type="aff" rid="af1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Manojlovic</surname>
              <given-names initials="Z">Zarko</given-names>
            </name>
            <xref ref-type="aff" rid="af1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Halperin</surname>
              <given-names initials="RF">Rebecca F.</given-names>
            </name>
            <xref ref-type="aff" rid="af1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Helland</surname>
              <given-names initials="A">Adrienne</given-names>
            </name>
            <xref ref-type="aff" rid="af1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Nasser</surname>
              <given-names initials="S">Sara</given-names>
            </name>
            <xref ref-type="aff" rid="af1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Legendre</surname>
              <given-names initials="C">Christophe</given-names>
            </name>
            <xref ref-type="aff" rid="af1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Hurley</surname>
              <given-names initials="LH">Laurence H.</given-names>
            </name>
            <xref ref-type="aff" rid="af3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Sivaprakasam</surname>
              <given-names initials="K">Karthigayini</given-names>
            </name>
            <xref ref-type="aff" rid="af1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Johnson</surname>
              <given-names initials="DB">Douglas B.</given-names>
            </name>
            <xref ref-type="aff" rid="af4">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Crandall</surname>
              <given-names initials="H">Holly</given-names>
            </name>
            <xref ref-type="aff" rid="af4">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Busam</surname>
              <given-names initials="KJ">Klaus J.</given-names>
            </name>
            <xref ref-type="aff" rid="af5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Zismann</surname>
              <given-names initials="V">Victoria</given-names>
            </name>
            <xref ref-type="aff" rid="af1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Deluca</surname>
              <given-names initials="V">Valerie</given-names>
            </name>
            <xref ref-type="aff" rid="af1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Lee</surname>
              <given-names initials="J">Jeeyun</given-names>
            </name>
            <xref ref-type="aff" rid="af6">6</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Sekulic</surname>
              <given-names initials="A">Aleksandar</given-names>
            </name>
            <xref ref-type="aff" rid="af1">1</xref>
            <xref ref-type="aff" rid="af2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Ariyan</surname>
              <given-names initials="CE">Charlotte E.</given-names>
            </name>
            <xref ref-type="aff" rid="af5">5</xref>
            <xref ref-type="author-notes" rid="FN1">8</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Sosman</surname>
              <given-names initials="J">Jeffrey</given-names>
            </name>
            <xref ref-type="aff" rid="af7">7</xref>
            <xref ref-type="author-notes" rid="FN1">8</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Trent</surname>
              <given-names initials="J">Jeffrey</given-names>
            </name>
            <xref ref-type="aff" rid="af1">1</xref>
            <xref ref-type="author-notes" rid="FN1">8</xref>
          </contrib>
        </contrib-group>
        <aff id="af1"><label>1</label>Translational Genomics Research Institute, Phoenix, Arizona 85004, USA;</aff>
        <aff id="af2"><label>2</label>Mayo Clinic, Scottsdale, Arizona 85259, USA;</aff>
        <aff id="af3"><label>3</label>University of Arizona, College of Pharmacy, Tucson, Arizona 85721, USA;</aff>
        <aff id="af4"><label>4</label>Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA;</aff>
        <aff id="af5"><label>5</label>Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA;</aff>
        <aff id="af6"><label>6</label>Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, Korea;</aff>
        <aff id="af7"><label>7</label>Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA</aff>
        <author-notes>
          <fn fn-type="equal" id="FN1">
            <label>8</label>
            <p>These authors contributed equally to this work.</p>
          </fn>
          <corresp>Corresponding author: <email>jtrent@tgen.org</email></corresp>
        </author-notes>
        <pub-date pub-type="ppub">
          <month>4</month>
          <year>2017</year>
        </pub-date>
        <volume>27</volume>
        <issue>4</issue>
        <issue-id pub-id-type="pmc-issue-id">290396</issue-id>
        <fpage>524</fpage>
        <lpage>532</lpage>
        <history>
          <date date-type="received">
            <day>25</day>
            <month>7</month>
            <year>2016</year>
          </date>
          <date date-type="accepted">
            <day>24</day>
            <month>1</month>
            <year>2017</year>
          </date>
        </history>
        <pub-history>
          <event event-type="pmc-release">
            <date>
              <day>01</day>
              <month>10</month>
              <year>2017</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>01</day>
              <month>10</month>
              <year>2017</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2022-11-14 12:10:16.227">
              <day>14</day>
              <month>11</month>
              <year>2022</year>
            </date>
          </event>
        </pub-history>
        <permissions>
          <copyright-statement>
            <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://genome.cshlp.org/site/misc/terms.xhtml">© 2017 Liang et al.; Published by Cold Spring Harbor Laboratory Press</ext-link>
          </copyright-statement>
          <copyright-year>2017</copyright-year>
          <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
            <license-p>This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see <ext-link ext-link-type="uri" xlink:href="http://genome.cshlp.org/site/misc/terms.xhtml">http://genome.cshlp.org/site/misc/terms.xhtml</ext-link>). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p>
          </license>
        </permissions>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="524.pdf"/>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="524.pdf"/>
        <abstract>
          <p>Genomic analyses of cutaneous melanoma (CM) have yielded biological and therapeutic insights, but understanding of non-ultraviolet (UV)-derived CMs remains limited. Deeper analysis of acral lentiginous melanoma (ALM), a rare sun-shielded melanoma subtype associated with worse survival than CM, is needed to delineate non-UV oncogenic mechanisms. We thus performed comprehensive genomic and transcriptomic analysis of 34 ALM patients. Unlike CM, somatic alterations were dominated by structural variation and absence of UV-derived mutation signatures. Only 38% of patients demonstrated driver <italic toggle="yes">BRAF/NRAS/NF1</italic> mutations. In contrast with CM, we observed <italic toggle="yes">PAK1</italic> copy gains in 15% of patients, and somatic <italic toggle="yes">TERT</italic> translocations, copy gains, and missense and promoter mutations, or germline events, in 41% of patients. We further show that in vitro TERT inhibition has cytotoxic effects on primary ALM cells. These findings provide insight into the role of <italic toggle="yes">TERT</italic> in ALM tumorigenesis and reveal preliminary evidence that TERT inhibition represents a potential therapeutic strategy in ALM.</p>
        </abstract>
        <funding-group>
          <award-group id="funding-1">
            <funding-source>Melanoma Research Alliance (MRA) <named-content content-type="funder-id">http://dx.doi.org/10.13039/100005190</named-content></funding-source>
          </award-group>
          <award-group id="funding-2">
            <funding-source>TGen</funding-source>
          </award-group>
          <award-group id="funding-3">
            <funding-source>TGen Foundation</funding-source>
          </award-group>
          <award-group id="funding-4">
            <funding-source>Stand Up To Cancer (SU2C)</funding-source>
          </award-group>
          <award-group id="funding-5">
            <funding-source>Melanoma Research Alliance <named-content content-type="funder-id">http://dx.doi.org/10.13039/100005190</named-content></funding-source>
            <award-id>SU2C-AACR-DT0612</award-id>
          </award-group>
        </funding-group>
        <counts>
          <page-count count="9"/>
        </counts>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
    <body>
      <p>Comprehensive sequencing of large cancer cohorts has revealed genomic landscapes of common malignant diseases, enabling deduction of tumorigenic pathways and clinically actionable information. Such genomic analyses of more than 600 cutaneous melanomas (CM), the most common melanoma subtype, have identified a small number of frequent driver mutations (impacting <italic toggle="yes">BRAF</italic>, <italic toggle="yes">NRAS</italic>, and <italic toggle="yes">NF1)</italic>, a large number of low-frequency mutations, and a complex array of genotypes reflecting diverse paths to tumorigenesis (for review, see <xref rid="LIANGGR213348C50" ref-type="bibr">Zhang et al. (2016)</xref>). Although all melanomas arise from transformed melanocytes, the genetics, biology, and pathology of melanoma subtypes are shaped by anatomic location (cutaneous or acral skin, mucosal surfaces, or the eye), host-tumor microenvironment, and the unique mutational processes at work in each location. Mapping the relatively uncharted landscapes of melanoma in noncutaneous sites will have broad relevance for understanding melanoma biology and clinical management.</p>
      <p>Acral lentiginous melanoma (ALM), first described in <xref rid="LIANGGR213348C37" ref-type="bibr">Reed (1976)</xref>, is a rare subtype of non-CM. Although there is debate about ALM's distinctive histologic features, it is characterized by occurrence in sun-shielded skin sites on palms, soles, or nail beds (subungual). It comprises 2%–3% of melanoma cases in the United States and is more prevalent than CM in heavily pigmented ethnic populations with an age-adjusted incidence rate of 1.8 per 1,000,000 persons/year (<xref rid="LIANGGR213348C6" ref-type="bibr">Bradford et al. 2009</xref>). ALM has a worse prognosis than CM, demonstrating inferior 10-yr and overall survival rates (<xref rid="LIANGGR213348C6" ref-type="bibr">Bradford et al. 2009</xref>; <xref rid="LIANGGR213348C4" ref-type="bibr">Bello et al. 2013</xref>). Unfortunately, understanding of ALM's genomic landscape remains limited. Analysis of small ALM cohorts by next-generation or targeted sequencing has revealed a low single-nucleotide variant (SNV) and high structural variant (SV) burden (<xref rid="LIANGGR213348C13" ref-type="bibr">Curtin et al. 2005</xref>; <xref rid="LIANGGR213348C44" ref-type="bibr">Turajlic et al. 2012</xref>; <xref rid="LIANGGR213348C17" ref-type="bibr">Furney et al. 2014</xref>). Notably, CM bears the highest mutation burden of any cancer due to DNA damage from ultraviolet (UV) radiation, an established melanoma risk factor. UV induces characteristic C &gt; T transitions at dipyrimidines that occur in &gt;76% of CMs with variability based on anatomic site and degree of sun exposure (<xref rid="LIANGGR213348C8" ref-type="bibr">The Cancer Genome Atlas Network 2015</xref>). A UV signature is present when C &gt; T transitions at dipyrimidine sites account for &gt;60%, or CC &gt; TT mutations account for &gt;5%, of the total mutation burden. UV signatures are less frequent in ALM in keeping with lower SNV burden and occurrence in sun-shielded sites, although exceptions have been reported (<xref rid="LIANGGR213348C44" ref-type="bibr">Turajlic et al. 2012</xref>; <xref rid="LIANGGR213348C17" ref-type="bibr">Furney et al. 2014</xref>). Driver mutations implicated in ALM include mutations at <italic toggle="yes">BRAF</italic> (B-Raf proto-oncogene) V600 (reported in ∼15% of ALMs) (<xref rid="LIANGGR213348C8" ref-type="bibr">The Cancer Genome Atlas Network 2015</xref>) and in <italic toggle="yes">KIT</italic> (KIT proto-oncogene receptor tyrosine kinase; reported in ∼11% of ALMs) (<xref rid="LIANGGR213348C14" ref-type="bibr">Curtin et al. 2006</xref>) in addition to focal amplifications involving <italic toggle="yes">CCND1</italic> (cyclin D1), <italic toggle="yes">CDK4</italic> (cyclin dependent kinase 4), and <italic toggle="yes">GAB2</italic> (GRB2-associated binding protein 2) (<xref rid="LIANGGR213348C39" ref-type="bibr">Sauter et al. 2002</xref>; <xref rid="LIANGGR213348C13" ref-type="bibr">Curtin et al. 2005</xref>; <xref rid="LIANGGR213348C10" ref-type="bibr">Chernoff et al. 2009</xref>; <xref rid="LIANGGR213348C28" ref-type="bibr">Krauthammer et al. 2012</xref>). Finally, <italic toggle="yes">TERT</italic> (telomerase reverse transcriptase) promoter mutations driving <italic toggle="yes">TERT</italic> overexpression occur as an early tumorigenic event in &gt;70% of CMs (<xref rid="LIANGGR213348C20" ref-type="bibr">Horn et al. 2013</xref>; <xref rid="LIANGGR213348C21" ref-type="bibr">Huang et al. 2013</xref>; <xref rid="LIANGGR213348C18" ref-type="bibr">Griewank et al. 2014</xref>), resulting from C &gt; T transitions reflective of UV mutagenesis, and often in cooperation with <italic toggle="yes">BRAF</italic> mutations. These events are more rare in ALM with a recent report identifying <italic toggle="yes">TERT</italic> promoter mutations in 9.3% of 48 ALMs (<xref rid="LIANGGR213348C15" ref-type="bibr">de Lima Vazquez et al. 2016</xref>). The unique etiology of non-UV and non-CM melanoma still remains to be understood. Further, targeted treatment for ALM is limited. To date, <italic toggle="yes">KIT</italic> and <italic toggle="yes">BRAF</italic> mutations, although infrequent, have been the focus of targeted therapy for ALM. It is thus critical to define additional targetable genomic or transcriptomic alterations in ALM. To address these needs, we performed comprehensive, integrated genomic and transcriptomic analysis of 38 ALMs from 34 patients with detailed clinical annotation, along with downstream in vitro analyses based on our findings. These data establish a foundation for understanding ALM's genetic etiology with the ultimate goal to inform ALM clinical management.</p>
      <sec sec-type="results" id="s1">
        <title>Results</title>
        <sec id="s1a">
          <title>The genomic and transcriptomic landscape of ALM</title>
          <p>Patient information is shown in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://genome.cshlp.org/lookup/suppl/doi:10.1101/gr.213348.116/-/DC1">Supplemental Tables S1A,B</ext-link>, and overall survival and progression-free survival analyses are shown in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://genome.cshlp.org/lookup/suppl/doi:10.1101/gr.213348.116/-/DC1">Supplemental Figure S1A,B</ext-link>. Paired tumor/constitutional exome sequencing was performed across 33 patients, and tumor-only exome sequencing was performed for the 34th patient, for whom constitutional DNA was not available (Methods). For 32 patients, sufficient amounts of DNA were extracted to support additional analysis using long-insert whole-genome (LIWG) sequencing of ∼900 bp inserts to identify breakpoints that reflect structural variants (SVs) in the form of copy number variants (CNVs) and translocations (<xref rid="LIANGGR213348C31" ref-type="bibr">Liang et al. 2014</xref>). RNA-seq was additionally performed for 33 patients. A summary of assays performed and estimated tumor cellularities (median = 50%) are listed in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://genome.cshlp.org/lookup/suppl/doi:10.1101/gr.213348.116/-/DC1">Supplemental Table S2</ext-link>, and sequencing metrics are listed in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://genome.cshlp.org/lookup/suppl/doi:10.1101/gr.213348.116/-/DC1">Supplemental Table S3</ext-link>.</p>
          <p>Paired-exome sequencing across 34 patients led to the identification of 9522 somatic SNVs and 72 somatic small indels (SNV/small indel median = 116, range = 3–2278), including intronic, UTR, loss of function, missense, splice site (splicing altered or splice site loss), and synonymous events. With respect to coding somatic mutations (missense, nonsense, splice site, indels), a median of 42 mutations (range 0–869) across all tumors was observed (SNV mutation burden) (<xref ref-type="fig" rid="LIANGGR213348F1">Fig. 1</xref>). These findings are consistent with prior next-generation sequencing studies that have identified a relatively low ALM coding mutation burden with averages ranging from 9–80 somatic coding mutations per tumor dependent on platform, analysis, and cohort characteristics (<xref rid="LIANGGR213348C5" ref-type="bibr">Berger et al. 2012</xref>; <xref rid="LIANGGR213348C19" ref-type="bibr">Hodis et al. 2012</xref>; <xref rid="LIANGGR213348C28" ref-type="bibr">Krauthammer et al. 2012</xref>; <xref rid="LIANGGR213348C44" ref-type="bibr">Turajlic et al. 2012</xref>; <xref rid="LIANGGR213348C17" ref-type="bibr">Furney et al. 2014</xref>). Notably, the treatment status of sequenced tumors may also impact mutation burden as the tumor demonstrating the highest SNV burden in our study (patient 7; 867 coding SNVs) was collected following treatment with ipilimumab, followed by pembrolizumab (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://genome.cshlp.org/lookup/suppl/doi:10.1101/gr.213348.116/-/DC1">Supplemental Table S1B</ext-link>). Pretreated tumors were also sequenced for patients 4, 5, and 28, and the number of identified coding SNVs also trended toward higher levels for these patients (median = 75, range = 42–177). As secondary confirmation of somatic coding point mutations identified in our study, 12% of these events were confirmed by LIWG data in tumors with both exome and LIWG data, noting the lower coverage for LIWG sequencing. Furthermore, 90% of somatic coding point mutations were confirmed in RNA-seq data in tumors with both exome and RNA-seq data.</p>
          <fig id="LIANGGR213348F1" orientation="portrait" position="float">
            <label>Figure 1.</label>
            <caption>
              <p>The mutational landscape of ALM. A summary of somatic alterations is shown. Patients for whom multiple tumors were sequenced are shown with partially shaded rectangles on the <italic toggle="yes">bottom</italic> row.</p>
            </caption>
            <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="524f01.jpg"/>
          </fig>
          <p>Overall, C &gt; T transitions, which have a 75% probability of occurring in dipyrimidine sequences (<xref rid="LIANGGR213348C7" ref-type="bibr">Brash 2015</xref>), were the most common base substitution in the ALMs analyzed here, making up 55.0% of all identified somatic point mutations (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://genome.cshlp.org/lookup/suppl/doi:10.1101/gr.213348.116/-/DC1">Supplemental Fig. S2</ext-link>). Across all patients, 39.4% of C &gt; T transitions occurred in dipyrimidine sequences, which falls short of the 60% threshold that characterizes the presence of a dominant UV signature (<xref rid="LIANGGR213348C7" ref-type="bibr">Brash 2015</xref>; <xref rid="LIANGGR213348C8" ref-type="bibr">The Cancer Genome Atlas Network 2015</xref>) observed in CMs, such that a more minor signature may be present. However, individual analysis of each tumor revealed the presence of a UV signature in two ALMs (<xref ref-type="fig" rid="LIANGGR213348F1">Fig. 1</xref>), with patient 7 demonstrating a trend toward the presence of a signature with 59% of C &gt; T transitions occurring at dipyrimidines.</p>
          <p>SNVs identified through exome sequencing, along with respective sequence contexts, were used to characterize somatic mutational signatures across all tumors (Methods). The distribution of signatures across tumors and the context of each identified signature are shown in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://genome.cshlp.org/lookup/suppl/doi:10.1101/gr.213348.116/-/DC1">Supplemental Figure S3, A and B</ext-link>, respectively. Analysis of variance (ANOVA) indicated that differences in the frequency of signatures across all samples was not statistically significant (<italic toggle="yes">P</italic> = 0.699). Correlation of the identified signatures against previously reported somatic cancer signatures (<xref rid="LIANGGR213348C2" ref-type="bibr">Alexandrov et al. 2013</xref>) was also performed (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://genome.cshlp.org/lookup/suppl/doi:10.1101/gr.213348.116/-/DC1">Supplemental Table S4</ext-link>). Overall, the most common ALM signature that was identified is S1, with an incidence of 0.658 across samples. ALM signature S1 (cosine similarity value [CSV] = 0.981) correlated with the Alexandrov UV light signature (Alexandrov signature S7) and was also the dominant signature for samples 7, 15, 24, 25a, and 25b. Notably, these patients overlap with the patients for whom UV signatures were previously identified (patients 25 and 15) from analysis of C &gt; T transitions in dipyrimidines. These findings provide evidence of a putative UV signature in a small subset of patients. We additionally observed limited correlation between ALM signature S4 and Alexandrov signature S1A (CSV = 0.846), as well as between ALM signatures S7 and S10 with Alexandrov signature S1B (CSV = 0.710–0.761). Alexandrov signatures S1A and S1B were previously reported across 83% of cancer classes analyzed and may be associated with increased spontaneous deamination of 5-methyl-cytosine events resulting in C &gt; T transitions in both normal and cancerous cells (<xref rid="LIANGGR213348C2" ref-type="bibr">Alexandrov et al. 2013</xref>).</p>
          <p>Analysis of somatic coding SNVs and small indels revealed <italic toggle="yes">NRAS</italic> and <italic toggle="yes">BRAF</italic> as the most significant putative drivers in ALM. Three patients demonstrated the well-recognized activating <italic toggle="yes">NRAS</italic> (neuroblastoma RAS viral oncogene homolog) Q61K (9%) hotspot mutation that has been reported in CMs (<xref rid="LIANGGR213348C8" ref-type="bibr">The Cancer Genome Atlas Network 2015</xref>), which was validated in two of three patients based on available DNA, and a fourth demonstrated an A59G event. With respect to <italic toggle="yes">BRAF</italic> alterations, four patients each demonstrated V600E (12%), a fifth demonstrated a G466E mutation, and a sixth demonstrated two separate <italic toggle="yes">BRAF</italic> mutations (V600K, R462K). The <italic toggle="yes">NRAS</italic> and <italic toggle="yes">BRAF</italic> events were mutually exclusive (<xref ref-type="fig" rid="LIANGGR213348F1">Fig. 1</xref>), and these putative driving events occurred in 10 of the 34 assayed patients (29%), indicating that the remaining 24 patients garner unique driving alterations. Previous studies also reported the presence of mutually exclusive mutant <italic toggle="yes">BRAF</italic> and mutant <italic toggle="yes">NRAS</italic> in ALMs (<xref rid="LIANGGR213348C13" ref-type="bibr">Curtin et al. 2005</xref>; <xref rid="LIANGGR213348C28" ref-type="bibr">Krauthammer et al. 2012</xref>), in addition to <italic toggle="yes">KIT</italic> mutations in 11% of ALMs (<xref rid="LIANGGR213348C14" ref-type="bibr">Curtin et al. 2006</xref>). However, in our analysis, we identified only one patient with a <italic toggle="yes">KIT</italic> L576P mutation, that was exclusive of driving <italic toggle="yes">BRAF/NRAS</italic> events, and that was previously reported in ALM patients (<xref rid="LIANGGR213348C28" ref-type="bibr">Krauthammer et al. 2012</xref>). No correlation was observed between mutation burden and <italic toggle="yes">BRAF</italic> or <italic toggle="yes">NRAS</italic> mutation status.</p>
          <p>In addition to these driving events, we also observed low incidence of somatic mutations in other key genes, including <italic toggle="yes">NF1</italic> (neurofibromin 1), <italic toggle="yes">EGFR</italic> (epidermal growth factor receptor), <italic toggle="yes">KRAS</italic> (KRAS proto-oncogene, GTPase), and <italic toggle="yes">TP53</italic> (tumor protein p53) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://genome.cshlp.org/lookup/suppl/doi:10.1101/gr.213348.116/-/DC1">Supplemental Table S5</ext-link>). We observed homozygous loss of <italic toggle="yes">NF1</italic> in 9% of patients (<xref ref-type="fig" rid="LIANGGR213348F1">Fig. 1</xref>), and in a fourth patient (19), loss of heterozygosity (LOH) of <italic toggle="yes">NF1</italic> was accompanied by a nonsense mutation (E2578*) on the second allele. Additional somatic mutations were identified in <italic toggle="yes">EGFR</italic> (R334C, V726M), <italic toggle="yes">KRAS</italic> (V14L with a CNV gain in patient 5), <italic toggle="yes">TP53</italic> (R248W), and <italic toggle="yes">ERBB3</italic> (erb-b2 receptor tyrosine kinase 3; S1119C). Two nonsynonymous events were also detected (patients 11 [S1167T] and 24 [A355T]) in <italic toggle="yes">PREX2</italic> (phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 2), which has been reported to be frequently mutated in CM (<xref rid="LIANGGR213348C5" ref-type="bibr">Berger et al. 2012</xref>). These two point mutations have not been described in melanoma, but the S1167 position was found to also be mutated in a CM metastasis (S1167N) (<xref rid="LIANGGR213348C28" ref-type="bibr">Krauthammer et al. 2012</xref>).</p>
          <p>We additionally performed mutational landscape analyses by segregating primary from metastatic tumors. Although no novel drivers emerged, <italic toggle="yes">BRAF</italic> remained significant (IntOgen; <italic toggle="yes">Q</italic>-value &lt; 0.05) in both groups. UV signatures were also absent in each group, and mutation burden differences trended toward significance (<italic toggle="yes">P</italic> = 0.06) with a higher number of mutations in metastases (mean = 113) compared to primary ALMs (mean = 50).</p>
        </sec>
        <sec id="s1b">
          <title>Structural alterations in ALM</title>
          <p>Across 31 patients with LIWG data, a total of 2490 somatic breakpoints, in the form of inversions, large indels, or translocations, were identified across 74% of patients (25 ALMs; median = 31, range = 0–683) (<xref ref-type="fig" rid="LIANGGR213348F1">Figs. 1</xref>, <xref ref-type="fig" rid="LIANGGR213348F2">2</xref>; genic breakpoints listed in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://genome.cshlp.org/lookup/suppl/doi:10.1101/gr.213348.116/-/DC1">Supplemental Table S6</ext-link>; tumor-specific SVs are shown in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://genome.cshlp.org/lookup/suppl/doi:10.1101/gr.213348.116/-/DC1">Supplemental Fig. S3</ext-link>). Notably, patient 14 showed evidence of chromothripsis with 503 breakpoints on Chromosome 12. Patients 24 and 29c additionally demonstrated a high number (more than 200), with 242 total events falling within Chromosome 11 for patient 24 and 135 breakpoints falling within Chromosome 5 for patient 29c. Overall, two genes were found to be most highly impacted across the cohort—these include <italic toggle="yes">ADCY2</italic> (adenylate cyclase 2), for which 32 breakpoints were identified across seven samples (21% of patients), and <italic toggle="yes">CLPTM1L</italic> (CLPTM1 like), for which 22 breakpoints were identified across six samples (15% of patients). <italic toggle="yes">ADCY2</italic> translocation partners include <italic toggle="yes">CLPTM1L</italic>, <italic toggle="yes">HECTD4</italic> (HECT domain containing E3 ubiquitin protein ligase 4), <italic toggle="yes">TERT</italic>, and <italic toggle="yes">UBE2QL1</italic> (ubiquitin conjugating enzyme E2Q family-like 1). <italic toggle="yes">CLPTM1L</italic> partners include <italic toggle="yes">ADCY2</italic>, <italic toggle="yes">PDZD2</italic> (PDZ domain containing 2), <italic toggle="yes">RAI14</italic> (retinoic acid induced 14), and <italic toggle="yes">TRIO</italic> (trio Rho guanine nucleotide exchange factor). These breakpoints all occurred in <italic toggle="yes">BRAF</italic> wild-type tumors.</p>
          <fig id="LIANGGR213348F2" orientation="portrait" position="float">
            <label>Figure 2.</label>
            <caption>
              <p>Consensus somatic SVs and CNVs. (<italic toggle="yes">A</italic>) Summary of somatic SVs and CNVs. Intrachromosomal SVs: (gray) &lt;1 Mb; (green) ≥1 Mb and &lt;50 Mb; (black) ≥50 Mb and &lt;100 Mb; (red) ≥100 Mb. Interchromosomal SVs are shown in red; interchromosomal SVs impacting Chr 5 are in yellow. Consensus CNVs are shown in the <italic toggle="yes">inner</italic> circle adjacent to chromosomes: (red) exome CNV gain; (green) LIWG CNV gain; (blue) exome CNV loss; (orange) LIWG CNV loss. (<italic toggle="yes">B</italic>) Consensus CNVs. Selected common gains and losses are indicated by green arrows. The percentage of impacted tumors is shown in parentheses. The plot shows the <italic toggle="yes">Q</italic>-values; Benjamini and Hochberg FDR (<italic toggle="yes">bottom</italic>) and G-score (<italic toggle="yes">top</italic>), with the copy number gains (<italic toggle="yes">left</italic>) indicated in red and copy number losses (<italic toggle="yes">right</italic>) in blue. Chromosome positions are indicated along the <italic toggle="yes">y</italic>-axis.</p>
            </caption>
            <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="524f02.jpg"/>
          </fig>
          <p>Overall, a total of 1115 somatic focal CNVs (median = 12, range = 0–211) (<xref ref-type="fig" rid="LIANGGR213348F2">Fig. 2</xref>A,B; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://genome.cshlp.org/lookup/suppl/doi:10.1101/gr.213348.116/-/DC1">Supplemental Fig. S3</ext-link>, tumor-specific CNVs) were identified. To identify statistically significant consensus CNVs across all samples, CNVs detected using either exome or LIWG data were integrated. As a result, 48 total CNVs were identified (95% confidence interval). CNVs include 40 deleted regions and eight amplified regions (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://genome.cshlp.org/lookup/suppl/doi:10.1101/gr.213348.116/-/DC1">Supplemental Table S7</ext-link>). Key events include <italic toggle="yes">TERT</italic> and <italic toggle="yes">CLPTM1L</italic> gains on Chr 5, loss of <italic toggle="yes">CDKN2A</italic> on Chr 9, and a gain in a region on Chr 12 encompassing <italic toggle="yes">CDK4</italic>. <italic toggle="yes">TERT</italic> gains were separately validated by real-time PCR for available samples (six of eight ALMs; 75%). Following segregation of samples based on primary or metastasis status, the <italic toggle="yes">TERT</italic> and <italic toggle="yes">CLPTM1L</italic> gains and the <italic toggle="yes">CDKN2A</italic> losses remained statistically significant even when the primary (<italic toggle="yes">Q</italic> = 1.28 × 10<sup>−4</sup>) or metastatic lesions (<italic toggle="yes">Q</italic> = 1.98 × 10<sup>−7</sup>) were analyzed separately. However, the <italic toggle="yes">CDK4</italic> gain only retained significance in metastases. Notably, relevant CNVs that were not previously observed in the analysis of all samples include <italic toggle="yes">PTEN</italic> (10q23.31) and <italic toggle="yes">NF1</italic> (17q11.2) deletions in only the primary tumors and gain of <italic toggle="yes">MDM2</italic> (MDM2 proto-oncogene; 12q15) in only metastases.</p>
          <p>Focal copy gains impacting <italic toggle="yes">PAK1</italic> were also observed in five (15%) patients, with one of these patients also demonstrating multiple SVs impacting <italic toggle="yes">PAK1</italic>, including evidence of multiple inversions and a large indel. <italic toggle="yes">PAK1</italic> gains were separately validated by real-time PCR for available samples (four of five ALMs; 80%). Elevated expression of <italic toggle="yes">PAK1</italic> was also observed in two of five patients (1, 10). These patients were exclusive of characteristic CM BRAF and RAS subtypes, with one patient demonstrating the NF1 subtype and the remaining four demonstrating the triple-wild-type (TWT) subtype, providing evidence that alternate routes toward dysregulation of MAPK signaling may be present in the TWT context.</p>
        </sec>
        <sec id="s1c">
          <title>RNA fusions</title>
          <p>Using RNA-seq data, we detected 106 RNA fusions across 74% of patients (median = 2) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://genome.cshlp.org/lookup/suppl/doi:10.1101/gr.213348.116/-/DC1">Supplemental Table S8</ext-link>). Thirteen of these fusions (13%) were also supported by the detection of a corresponding DNA breakpoint. Additional selected fusions include two <italic toggle="yes">MDM2</italic> events (<italic toggle="yes">MDM2:GNS</italic>, <italic toggle="yes">MDM2:CCT2</italic>), and <italic toggle="yes">PTEN:RPL11</italic>, <italic toggle="yes">PAK2:LOC646214</italic>, and <italic toggle="yes">MAP3K8:DEK</italic> fusions (each observed in a single tumor). <italic toggle="yes">MDM2</italic> structural breakpoints and overexpression were additionally observed in the respective patients with the reported fusions. However, no additional alterations in <italic toggle="yes">PTEN</italic> and <italic toggle="yes">PAK2</italic> were identified in the tumors demonstrating <italic toggle="yes">PTEN</italic> to <italic toggle="yes">PAK2</italic> fusions, but patient 28, who garners the <italic toggle="yes">MAP3K8</italic> fusion, also demonstrated a breakpoint adjacent to the fusion boundary.</p>
        </sec>
        <sec id="s1d">
          <title>Perturbed biological processes in ALM</title>
          <p>In order to evaluate the impact of identified mutations on pathways, we assessed somatic genomic alterations according to a manually curated set of commonly altered melanoma pathways (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://genome.cshlp.org/lookup/suppl/doi:10.1101/gr.213348.116/-/DC1">Supplemental Fig. S4A</ext-link>). These pathways include MAPK/PI3K (proliferation/survival, altered in 66% of patients), TERT (telomere maintenance, altered in 37% of patients), CDK4/CDKN2A (cell-cycle progression, altered in 51% of patients), and MDM2/TP53 (apoptosis and senescence, altered in 17% of patients). Next, we integrated gene expression data from 24 samples in order to identify transcriptionally dysregulated pathways in ALM and to pinpoint associations with genomic and clinical characteristics of these samples. Through unsupervised hierarchical clustering of the 421 genes with the greatest differential expression, we identified three dominant sample clusters (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://genome.cshlp.org/lookup/suppl/doi:10.1101/gr.213348.116/-/DC1">Supplemental Fig. S4B</ext-link>). Of note, these 421 genes did not include the melanogenesis associated transcription factor (<italic toggle="yes">MITF</italic>), which demonstrates key roles in CMs through regulation of melanocyte development and function. The three dominant clusters trended toward segregation of primary from metastatic samples, but did not significantly correlate with mutational profiles or other clinical features including age, gender, race, primary location, in-transit status, and response to immunotherapy. Five dominant gene clusters were present, including gene sets associated with (1) protein translation; (2) the ER stress response; (3) antigen presentation and immune processes; (4) keratinization, chemotaxis, and intermediate filaments; and (5) G2/M cell-cycle, pigmentation, and nonsense-mediated decay. Notably, cluster 4 containing keratin genes was down-regulated in metastases and overexpressed in primary tumors to parallel previous reports in CM (<xref rid="LIANGGR213348C8" ref-type="bibr">The Cancer Genome Atlas Network 2015</xref>).</p>
        </sec>
        <sec id="s1e">
          <title>Neo-antigen burden</title>
          <p>Although response to immune checkpoint inhibitors has been well demonstrated in CM (<xref rid="LIANGGR213348C41" ref-type="bibr">Snyder et al. 2014</xref>; <xref rid="LIANGGR213348C45" ref-type="bibr">Van Allen et al. 2015</xref>), it has not been well studied in ALM. In a previous retrospective analysis, 11% of ALM cases responded to ipilimumab, but the response rate to anti-PD1 has not been reported (<xref rid="LIANGGR213348C23" ref-type="bibr">Johnson et al. 2015</xref>). In this cohort, 22 patients received immune checkpoint inhibitors, with 10 receiving only anti-CTLA4 and 10 receiving both anti-CTLA4 and anti-PD1. In order to help inform utility of checkpoint blockade in ALM, we assessed neo-antigen burden and HLA expression in patients for whom both RNA and DNA data were available (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://genome.cshlp.org/lookup/suppl/doi:10.1101/gr.213348.116/-/DC1">Supplemental Fig. S5</ext-link>). Neo-antigen burden was associated with mutation burden (0.89, Pearson's correlation) as shown in studies of CM (<xref rid="LIANGGR213348C41" ref-type="bibr">Snyder et al. 2014</xref>; <xref rid="LIANGGR213348C45" ref-type="bibr">Van Allen et al. 2015</xref>; <xref rid="LIANGGR213348C22" ref-type="bibr">Hugo et al. 2016</xref>). Mutation and neo-antigen burden has been previously reported to be associated with response to immune checkpoint blockade (<xref rid="LIANGGR213348C41" ref-type="bibr">Snyder et al. 2014</xref>; <xref rid="LIANGGR213348C45" ref-type="bibr">Van Allen et al. 2015</xref>). Although we did not observe that trend here, the number of samples limits our power to detect such a correlation. Interestingly, we observed that two patients with complete response to anti-PD1, and one with complete response to anti-CTLA4 treatments had lower mutation (less than 75) and neo-antigen (less than 60) burdens.</p>
        </sec>
        <sec id="s1f">
          <title><italic toggle="yes">TERT</italic> alterations in ALM</title>
          <p>In addition to <italic toggle="yes">TERT</italic> gains, additional <italic toggle="yes">TERT</italic> events were also detected with a total of 14 (41%) patients demonstrating either somatic or germline aberrations in this gene. <italic toggle="yes">TERT</italic> promoter mutations were not initially identified because of limited coverage of the promoter region by exome baits. However, targeted Sanger sequencing of <italic toggle="yes">TERT</italic> promoters led to the identification of promoter mutations in 9% of patients (four of 28 ALMs; 15, 24, 25a, 25b) with available DNA (Chr 5: 1,295,113: G&gt;A) (<xref ref-type="fig" rid="LIANGGR213348F1">Fig. 1</xref>) to parallel previous reports (<xref rid="LIANGGR213348C32" ref-type="bibr">Liau et al. 2014</xref>; <xref rid="LIANGGR213348C15" ref-type="bibr">de Lima Vazquez et al. 2016</xref>). From exome sequencing, one nonsynonymous mutation in patient 12 (F919L) was also identified; in patient 24, an intronic SNV (Chr 5: 1,293,410: C &gt; A), which is localized to TERT's RNA-interacting domain and a region required for oligomerization, was observed. Notably, two rare germline polymorphisms were identified in patients 1 and 4 (A1062T) and 8 (T1110M) and were mutually exclusive of patients with somatic <italic toggle="yes">TERT</italic> events. Both these events are predicted to be damaging by FATHMM (<underline>f</underline>unctional <underline>a</underline>nalysis <underline>t</underline>hrough <underline>h</underline>idden <underline>M</underline>arkov <underline>m</underline>odels). One case, patient 1, additionally displayed LOH in tumor DNA.</p>
          <p>LIWG also supported the identification of <italic toggle="yes">TERT</italic> breakpoints in four patients (12, 17, 29a and 29c, 33). In patient 12, a breakpoint was identified at −:5:36,583,500|−:5:1,288,500. Patient 12's tumor demonstrated a complex rearrangement at the Chr 5p locus (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://genome.cshlp.org/lookup/suppl/doi:10.1101/gr.213348.116/-/DC1">Supplemental Fig. S6</ext-link>). This event encompasses an inversion in intron 11 of <italic toggle="yes">TERT</italic>, directly 3′ of exon 11, as well as a translocation impacting exon 11. The inversion is evidenced by <italic toggle="yes">TERT</italic> intron 11 reads with mates mapping to intron 3 of <italic toggle="yes">NIPBL</italic> (cohesion loading factor), whereas the translocation suggests loss of exon 11 of <italic toggle="yes">TERT</italic>. No RNA reads supporting a <italic toggle="yes">TERT:NIPBL</italic> fusion were found. However, RNA reads supporting an intra-exon translocation in exon 11 of <italic toggle="yes">TERT</italic> were observed. Because of the complexity of these events, it is unclear what the functional impact is, but in the same tumor, <italic toggle="yes">TERT</italic> expression is elevated with an FPKM of 32.5 (<xref ref-type="fig" rid="LIANGGR213348F3">Fig. 3</xref>) to suggest the possibility of <italic toggle="yes">TERT</italic> activation. Assembly of RNA-seq data of the same tumor also revealed the presence of a <italic toggle="yes">TERT:ADCY2</italic> RNA fusion. In patient 17, a breakpoint was also called in intron 2 of <italic toggle="yes">TERT</italic>, but closer evaluation indicated that this event falls in a GC-rich region with reads demonstrating low mapping quality. RNA-seq data indicated that this event was not expressed, coinciding with lower <italic toggle="yes">TERT</italic> expression in this tumor (FPKM &lt; 1). In both metastatic lesions from patient 29, a <italic toggle="yes">TERT:PDCD1LG2</italic> (<italic toggle="yes">PDL2</italic>; programmed cell death 1 ligand 2) interchromosomal rearrangement was identified (29a: −:5:1,272,000|+:9:5,560,500; 29c: −:5:1,271,200|+:9:5,560,800). Manual evaluation led to the observation that the breakpoint in <italic toggle="yes">TERT</italic> falls within Chr 5: 1,272,200–1,272,400, a region which encompasses exon 7 of the gene and which corresponds to the reverse transcriptase domain of <italic toggle="yes">TERT</italic>. This region is linked to intron 5 of <italic toggle="yes">PDCD1LG2</italic>. Although both <italic toggle="yes">TERT</italic> and <italic toggle="yes">PDCD1LG2</italic> were expressed in both tumors, expression of an RNA fusion was not observed. In both tumors, a possible inversion impacting <italic toggle="yes">TERT</italic> and <italic toggle="yes">FER</italic> (FER tyrosine kinase; −:5:108,410,400|+:5:1,276,800) was also detected. The breakpoints disrupt intron 6 of <italic toggle="yes">TERT</italic> and intron 16 of <italic toggle="yes">FER</italic>. Although both <italic toggle="yes">TERT</italic> and <italic toggle="yes">FER</italic> (29a FPKM = 6.7, 29c FPKM = 6.4) were expressed in both tumors, an RNA fusion resulting from this event was not detected. Lastly, a possible large indel was detected in patient 33. Upon closer inspection, this was determined to be an intrachromosomal rearrangement (−:5:7,752,000| +:5:1,294,500) between the 5′ UTR and exon 1 of <italic toggle="yes">TERT</italic> to intron 15 of <italic toggle="yes">ADCY2</italic>. A corresponding RNA fusion was not detected, and both expression of <italic toggle="yes">TERT</italic> and <italic toggle="yes">ADCY2</italic> were low in this patient's tumor (FPKM &lt; 1). Variable levels of expression of <italic toggle="yes">TERT</italic> were, however, observed across all patients (<xref ref-type="fig" rid="LIANGGR213348F3">Fig. 3</xref>).</p>
          <fig id="LIANGGR213348F3" orientation="portrait" position="float">
            <label>Figure 3.</label>
            <caption>
              <p><italic toggle="yes">TERT</italic> in ALM. (<italic toggle="yes">A</italic>) <italic toggle="yes">TERT</italic> aberrations in ALM. 41% of patients demonstrated <italic toggle="yes">TERT</italic> alterations (somatic, germline) and <italic toggle="yes">TERT</italic> expression. (<italic toggle="yes">B</italic>,<italic toggle="yes">C</italic>) TERT inhibition is selectively cytotoxic in ALM cell lines and reduces <italic toggle="yes">TERT</italic> expression. (<italic toggle="yes">B</italic>) Cell lines were treated with DMSO vehicle or Telomerase Inhibitor IX, and after 72 h cell viability was assessed by CellTiterGlo. Viability was reduced by at least 75% in ALM cell lines, but only 12% in normal melanocyte controls. (<italic toggle="yes">C</italic>) Cells were treated with DMSO vehicle or Telomerase Inhibitor IX, and after 72 h, <italic toggle="yes">TERT</italic> mRNA was quantified by reverse transcription and qPCR. Expression was reduced by at least 25% in ALM cell lines. NHM-002 <italic toggle="yes">TERT</italic> expression was undetectable.</p>
            </caption>
            <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="524f03.jpg"/>
          </fig>
        </sec>
        <sec id="s1g">
          <title>TERT inhibition in ALM</title>
          <p>To evaluate the impact of TERT inhibition in ALM, we performed viability assays on two primary ALM cell lines, one with a <italic toggle="yes">TERT</italic> CNV gain (SMC-09) and one with a homozygous <italic toggle="yes">TERT</italic> promoter mutation (SU2C-001-002; Chr 5: 1,295,113: G &gt; A [hg38]), as well as on a normal melanocyte line (NHM-002). Testing was performed using Telomerase inhibitor IX (<xref ref-type="fig" rid="LIANGGR213348F3">Fig. 3</xref>B,C) or vehicle. After 72 h of drug treatment, we observed at least a 75% decrease in cell viability with 2.5 µM of Telomerase Inhibitor IX, and not in normal melanocytes (<xref ref-type="fig" rid="LIANGGR213348F3">Fig. 3</xref>B). To explore the effect of telomerase inhibition on <italic toggle="yes">TERT</italic> gene expression, we treated the same ALM cells with 2.5 µM Telomerase Inhibitor IX, and measured <italic toggle="yes">TERT</italic> mRNA by qPCR after 72 h of drug treatment. <italic toggle="yes">TERT</italic> mRNA expression was also reduced at 72 h by at least 25% in the ALM cell lines and was undetected in normal melanocytes (<xref ref-type="fig" rid="LIANGGR213348F3">Fig. 3</xref>C). These data thus demonstrate that TERT inhibition may be an effective approach to reduce cell viability in <italic toggle="yes">TERT</italic>-dependent ALMs.</p>
        </sec>
      </sec>
      <sec sec-type="discussion" id="s2">
        <title>Discussion</title>
        <p>Our analysis of 38 ALMs across 34 patients confirms a number of findings of previous smaller analyses, but also sheds new light on the molecular foundations of human ALM. As others have, we observed lower SNV and higher SV burdens in ALMs (<xref rid="LIANGGR213348C17" ref-type="bibr">Furney et al. 2014</xref>) compared to CM. Importantly, in our study, pretreated tumors demonstrated elevated SNV burden, with one such tumor demonstrating the highest SNV burden in this cohort. UV signature analysis of the entire cohort based on the frequency of C &gt; T transitions in dipyrimidines revealed the absence of a dominant UV signature. However, two cases, both of which are <italic toggle="yes">BRAF</italic> mutant, individually demonstrated the presence of a UV signature, with one of these two cases also being the tumor with the greatest SNV burden. Secondary somatic signature analysis of SNVs, and sequence contexts of these events, additionally led to the identification of another two patients, in addition to the two previously identified cases, that demonstrate correlations with the previously defined cancer UV signature (<xref rid="LIANGGR213348C2" ref-type="bibr">Alexandrov et al. 2013</xref>) to provide evidence of the presence of this signature in a small subset of ALMs.</p>
        <p><italic toggle="yes">BRAF/NRAS</italic> mutant tumors did not demonstrate statistically significant differences from wild-type tumors with respect to SNV, CNV, or SV burden. These findings contrast with a previous analysis of sun-shielded melanomas, which reported a high number of CNVs and lower mutation load in <italic toggle="yes">BRAF</italic>/<italic toggle="yes">NRAS</italic> wild-type versus mutant melanomas (<xref rid="LIANGGR213348C28" ref-type="bibr">Krauthammer et al. 2012</xref>). We additionally observed a low number of <italic toggle="yes">BRAF</italic> mutations in ALMs to parallel previous reports of a lower incidence of <italic toggle="yes">BRAF</italic> alterations in sun-protected melanomas (<xref rid="LIANGGR213348C14" ref-type="bibr">Curtin et al. 2006</xref>). On the other hand, we did not observe any somatic SNVs or indels in <italic toggle="yes">DYNC1I1</italic> (dynein, cytoplasmic 1, intermediate chain 1), <italic toggle="yes">ARID1A</italic> (AT rich interaction domain 1A), and <italic toggle="yes">APC</italic> (APC, WNT signaling pathway regulator) (<xref rid="LIANGGR213348C17" ref-type="bibr">Furney et al. 2014</xref>), all of which have been reported to be recurrently mutated in ALM. Additional key findings include identification of <italic toggle="yes">PAK1</italic> copy gains in a subset of patients, all in the <italic toggle="yes">BRAF/NRAS</italic> wild-type context. <italic toggle="yes">PAK1</italic> has been proposed as a therapeutic target in <italic toggle="yes">BRAF</italic> wild-type melanoma (<xref rid="LIANGGR213348C35" ref-type="bibr">Ong et al. 2013</xref>) based on its activation in multiple tumors (<xref rid="LIANGGR213348C36" ref-type="bibr">Radu et al. 2014</xref>) as demonstrated by increased cell proliferation, survival, invasion, and metastasis pathways.</p>
        <p>In 41% of acral melanoma patients, we observed <italic toggle="yes">TERT</italic> aberrations encompassing promoter regions and point mutations, breakpoints, copy gains, and coding germline mutations. All ALMs with <italic toggle="yes">TERT</italic> copy gains were also all <italic toggle="yes">BRAF</italic> wild type, but overlapped with <italic toggle="yes">N/KRAS</italic> and <italic toggle="yes">NF1</italic> alterations, and trended toward higher levels of somatic alterations. We also identified potentially damaging germline point mutations in <italic toggle="yes">TERT</italic>. Although <italic toggle="yes">TERT</italic> promoter germline mutations have been described in melanoma (<xref rid="LIANGGR213348C20" ref-type="bibr">Horn et al. 2013</xref>), nonsynonymous coding germline mutations have not been reported. <italic toggle="yes">TERT</italic> breakpoints were observed in 12% of patients. Although one tumor demonstrated elevated <italic toggle="yes">TERT</italic> expression, it remains to be clarified if and how these genomic events may result in <italic toggle="yes">TERT</italic> activation. In addition to observed somatic <italic toggle="yes">TERT</italic> SVs, breakpoints were also identified in <italic toggle="yes">CLPTM1L</italic>, which is 5′ to <italic toggle="yes">TERT</italic> on Chr 5. Breakpoints impacting <italic toggle="yes">CLPTM1L</italic> have been observed in two ALM patients (<xref rid="LIANGGR213348C5" ref-type="bibr">Berger et al. 2012</xref>; <xref rid="LIANGGR213348C17" ref-type="bibr">Furney et al. 2014</xref>), and a <italic toggle="yes">CLPTM1L:ADCY2</italic> translocation has also been reported in one ALM patient (<xref rid="LIANGGR213348C17" ref-type="bibr">Furney et al. 2014</xref>). Notably, single nucleotide polymorphisms (SNPs) within the <italic toggle="yes">TERT-CLPTM1L</italic> locus have been reported to influence risk of developing melanoma (<xref rid="LIANGGR213348C29" ref-type="bibr">Law et al. 2012</xref>) and other cancers (<xref rid="LIANGGR213348C9" ref-type="bibr">Carvajal-Carmona et al. 2015</xref>; <xref rid="LIANGGR213348C33" ref-type="bibr">Liu et al. 2015</xref>; <xref rid="LIANGGR213348C49" ref-type="bibr">Zhang et al. 2015</xref>; <xref rid="LIANGGR213348C3" ref-type="bibr">Bei et al. 2016</xref>). Furthermore, SVs identified on Chr 5p are adjacent to, or fall within, reported super enhancers (<xref rid="LIANGGR213348C25" ref-type="bibr">Khan and Zhang 2016</xref>; <xref rid="LIANGGR213348C47" ref-type="bibr">Wei et al. 2016</xref>) and may thus impact transcription. In our analyses, the same patients who garnered a <italic toggle="yes">CLPTM1L</italic> SV also demonstrate at least one somatic <italic toggle="yes">TERT</italic> aberration (SV or copy gain) to provide evidence that <italic toggle="yes">TERT</italic> may be impacted by events proximal to the gene. Notably, corresponding expressed RNA fusions were not detected for identified SVs impacting <italic toggle="yes">TERT</italic>, with the exception that patient 12, whose tumor demonstrated a complex rearrangement encompassing <italic toggle="yes">TERT</italic>, also expressed a <italic toggle="yes">TERT:ADCY2</italic> fusion. Overall, all patients with somatic <italic toggle="yes">TERT</italic> events showed expression of <italic toggle="yes">TERT</italic>, which is reported to be overexpressed in &gt;90% of cancers (<xref rid="LIANGGR213348C27" ref-type="bibr">Kim et al. 1994</xref>; <xref rid="LIANGGR213348C40" ref-type="bibr">Shay and Bacchetti 1997</xref>). Importantly, normal cells typically lack telomerase activity and bear 0.004 RNA molecules on average, whereas in tumor cells, 0.2 <italic toggle="yes">TERT</italic> transcripts can lead to activation, although tumors may express hundreds of <italic toggle="yes">TERT</italic> transcripts per cell (<xref rid="LIANGGR213348C48" ref-type="bibr">Yi et al. 2001</xref>; <xref rid="LIANGGR213348C1" ref-type="bibr">Akıncılar et al. 2015</xref>). Lastly, our observation that TERT inhibition (in the context of <italic toggle="yes">TERT</italic> promoter mutation or CNV gain) successfully decreases ALM cell viability provides evidence that targeting <italic toggle="yes">TERT</italic> under aberrant conditions may be efficacious in ALM. This novel finding is particularly relevant given that <italic toggle="yes">TERT</italic> has been described as a driver in CM but has not been appreciated as a potential driver in ALM.</p>
        <p>Although ALM is defined as occurring on sun-shielded plantar locations, its etiological relationship to sun-shielded CM has been unclear. Characterization of ALM thus simultaneously establishes a foundation for understanding tumorigenic mechanisms in this rare subtype as well as supports the development and identification of efficacious treatment options for patients. In doing so, the unveiling of non-UV-derived drivers and oncogenic mechanisms may lend insight into other cancers, beyond sun-shielded CM, and may ultimately also benefit these patients. Based on our findings of <italic toggle="yes">TERT</italic> alterations in nearly half of ALMs analyzed here—and while further functional studies are necessary to verify the impact of such aberrations on TERT activity—TERT inhibitors represent a putative therapeutic strategy in ALM. This finding parallels recent work showing that pharmacological repression of <italic toggle="yes">TERT</italic> expression in melanoma cells leads to cell death (<xref rid="LIANGGR213348C24" ref-type="bibr">Kang et al. 2016</xref>). This is especially important since ALM has a limited number of targeted treatment options. Continued characterization of ALM and evaluation of the functional implications of <italic toggle="yes">TERT</italic> aberrations hold promise for paving an avenue toward improving outcomes for ALM patients.</p>
      </sec>
      <sec sec-type="methods" id="s3">
        <title>Methods</title>
        <sec id="s3a">
          <title>Patient enrollment and consent</title>
          <p>Patients in this study were enrolled from either Vanderbilt University or the Memorial Sloan-Kettering Cancer Center (MSKCC). At Vanderbilt and MSKCC, all patients were consented on a protocol approved by the institutional review board (IRB). Samples were obtained in accordance with standard biopsy or surgical procedures. Tissue was selected by the pathologist to limit the amount of necrotic tissue and placed into a vial and submerged into a liquid nitrogen container.</p>
        </sec>
        <sec id="s3b">
          <title>Sample collection</title>
          <p>For MSKCC cases, adjacent normal tissue was collected, and for Vanderbilt cases, a tube of blood was collected during routine blood drawing, for DNA extraction of germline DNA. An H+E slide was made to confirm normal or malignant tissue and &lt;50% necrosis, which was reviewed by the pathologist.</p>
          <p>For three patients, multiple tumors were collected for analysis—for patient 25, two metastases were collected; for patient 29, the primary (29b) and two metastases (29a, 29c) were collected; and for patient 34, a primary (34b) and metastasis (34a) were collected. All specimens were fresh frozen with the exception of 34b, which was formalin-fixed and paraffin embedded (FFPE).</p>
        </sec>
        <sec id="s3c">
          <title>Next-generation sequencing and analysis</title>
          <p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://genome.cshlp.org/lookup/suppl/doi:10.1101/gr.213348.116/-/DC1">Supplemental Methods</ext-link> provides details on sample preparation, sequencing, data analysis, and experimental validations. In brief, paired tumor/normal whole exomes and long-insert whole-genome, as well as tumor RNA, libraries were constructed and sequenced on the Illumina HiSeq using V3 reagents. FASTQs were aligned to build 37 of the human genome using BWA (Burrows–Wheeler Aligner) (<xref rid="LIANGGR213348C30" ref-type="bibr">Li and Durbin 2009</xref>). Somatic variants were identified by requiring detection by two of three callers (Seurat; quality score&gt;30) (<xref rid="LIANGGR213348C11" ref-type="bibr">Christoforides et al. 2013</xref>), MuTect (<xref rid="LIANGGR213348C12" ref-type="bibr">Cibulskis et al. 2013</xref>), and Strelka (<xref rid="LIANGGR213348C38" ref-type="bibr">Saunders et al. 2012</xref>). LIWG data were utilized for copy number and breakpoint detection analyses (<xref rid="LIANGGR213348C31" ref-type="bibr">Liang et al. 2014</xref>). A minimum tumor allele ratio of 0.10 and a minimum quality score (depth) of 20 is required for an SV to be called. For CNV detection, normalized log<sub>2</sub> fold-changes between tumor and normal are calculated, and a smoothing window is applied. In addition, we used allele frequencies in the tumor of known heterozygous germline SNPs identified within the normal to both evaluate potential false positives and correct biases. Lastly, we applied a circular binary segmentation (CBS) algorithm to corrected log<sub>2</sub> fold-changes using the Bioconductor DNAcopy implementation (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://bioconductor.org/packages/release/bioc/html/DNAcopy.html">https://bioconductor.org/packages/release/bioc/html/DNAcopy.html</uri>). RNA reads were aligned to build 37 of the human genome using STAR (<xref rid="LIANGGR213348C16" ref-type="bibr">Dobin et al. 2013</xref>), and differential analysis against a universal RNA control was performed using Cufflinks v2.2.1 Cuffdiff (<italic toggle="yes">Q</italic>-value &lt; 0.05) (<xref rid="LIANGGR213348C42" ref-type="bibr">Trapnell et al. 2010</xref>, <xref rid="LIANGGR213348C43" ref-type="bibr">2013</xref>) and DESeq2 (<italic toggle="yes">P-</italic>adjusted &lt; 0.05) (<xref rid="LIANGGR213348C34" ref-type="bibr">Love et al. 2014</xref>). RNA fusions were detected using TopHat-Fusion (quality score &gt; 100) (<xref rid="LIANGGR213348C26" ref-type="bibr">Kim and Salzberg 2011</xref>).</p>
          <p>Clinical and pathologic characteristics were collected from disease-specific databases. Survival curves were generated using the date of the pathologic diagnosis until death from melanoma or date of last follow-up. Analysis was performed using SAS software (v9.4) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://genome.cshlp.org/lookup/suppl/doi:10.1101/gr.213348.116/-/DC1">Supplemental Fig. S1A,B</ext-link>).</p>
        </sec>
        <sec id="s3d">
          <title>TERT inhibitor viability experiments</title>
          <p>Cell lines were plated in 96-well microplates, in 100 µL culture medium. Twenty-four hours after plating cells, dimethyl sulfoxide (DMSO) vehicle, or Telomerase Inhibitor IX (EMD Millipore) was diluted in culture medium and added to wells at 100 µL/well. Cell Titer Glo (Promega) was added to cells after 72 h of drug treatment. Plates were incubated at 37°C, and luminescence was measured using a FlexStation 3 microplate reader (Molecular Devices). The <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://genome.cshlp.org/lookup/suppl/doi:10.1101/gr.213348.116/-/DC1">Supplemental Methods</ext-link> provide details on quantitative PCR methods. In brief, qPCR was performed using the Kapa Fast qPCR master mix (Kapa Biosystems) and TaqMan probes.</p>
        </sec>
      </sec>
      <sec id="s4">
        <title>Data access</title>
        <p>The sequencing data from this study have been submitted to the NCBI Database of Genotypes and Phenotypes (dbGaP; <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/gap">https://www.ncbi.nlm.nih.gov/gap</uri>) under accession number phs001036.v1.p1.</p>
      </sec>
      <sec sec-type="supplementary-material">
        <title>Supplementary Material</title>
        <supplementary-material id="PMC_1" content-type="local-data" position="float" orientation="portrait">
          <caption>
            <title>Supplemental Material</title>
          </caption>
          <media xmlns:xlink="http://www.w3.org/1999/xlink" mimetype="text" mime-subtype="html" xlink:href="supp_27_4_524__index.html" position="float" orientation="portrait"/>
          <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_gr.213348.116_Supplemental_Methods.pdf" position="float" orientation="portrait"/>
          <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_gr.213348.116_Supplemental_Fig.pdf" position="float" orientation="portrait"/>
          <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:role="associated-file" mimetype="application" mime-subtype="vnd.ms-excel" xlink:href="supp_gr.213348.116_Supplemental_Tables.xlsx" position="float" orientation="portrait"/>
        </supplementary-material>
      </sec>
    </body>
    <back>
      <ack>
        <title>Acknowledgments</title>
        <p>This publication is based on research supported by the Melanoma Research Alliance (MRA) – Hidary Foundation Team Science Award for Acral Melanoma Genomics (J. Sosman, C.E. Ariyan, and J. Trent, PI’s). Additionally, the research was supported in part by TGen, the TGen Foundation, and a Stand Up To Cancer (SU2C) – Melanoma Research Alliance Melanoma Dream Team Translational Cancer Research Grant (#SU2C-AACR-DT0612). Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research. The authors thank the patients and their families for participating in this study. We additionally thank TGen's Seungchan Kim for RNA-seq analysis feedback; Jessica Aldrich, Daniel Enriquez, and Fatima Naveed for assistance with bioinformatics; and Cassandra Lucas, Cynthia Lechuga, and Kati Koktavy (TGen) for administrative support.</p>
      </ack>
      <fn-group>
        <fn fn-type="supplementary-material">
          <p>[Supplemental material is available for this article.]</p>
        </fn>
        <fn>
          <p>Article, supplemental material, and publication date are at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.genome.org/cgi/doi/10.1101/gr.213348.116">http://www.genome.org/cgi/doi/10.1101/gr.213348.116</ext-link>.</p>
        </fn>
      </fn-group>
      <ref-list>
        <title>References</title>
        <ref id="LIANGGR213348C1">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Akıncılar</surname><given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Low</surname><given-names>KC</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>CY</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>TD</given-names></string-name>, <string-name name-style="western"><surname>Oji</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ikawa</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Tergaonkar</surname><given-names>V</given-names></string-name>. <year>2015</year><article-title>Quantitative assessment of telomerase components in cancer cell lines</article-title>. <source>FEBS Lett</source><volume>589</volume>: <fpage>974</fpage>–<lpage>984</lpage>.<pub-id pub-id-type="pmid">25749370</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.febslet.2015.02.035</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C2">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Alexandrov</surname><given-names>LB</given-names></string-name>, <string-name name-style="western"><surname>Nik-Zainal</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wedge</surname><given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>Aparicio</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Behjati</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Biankin</surname><given-names>AV</given-names></string-name>, <string-name name-style="western"><surname>Bignell</surname><given-names>GR</given-names></string-name>, <string-name name-style="western"><surname>Bolli</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Borg</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Børresen-Dale</surname><given-names>AL</given-names></string-name>, <etal/><year>2013</year><article-title>Signatures of mutational processes in human cancer</article-title>. <source>Nature</source><volume>500</volume>: <fpage>415</fpage>–<lpage>421</lpage>.<pub-id pub-id-type="pmid">23945592</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature12477</pub-id><pub-id pub-id-type="pmcid">PMC3776390</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C3">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Bei</surname><given-names>JX</given-names></string-name>, <string-name name-style="western"><surname>Su</surname><given-names>WH</given-names></string-name>, <string-name name-style="western"><surname>Ng</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Chin</surname><given-names>YM</given-names></string-name>, <string-name name-style="western"><surname>Lou</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Hsu</surname><given-names>WL</given-names></string-name>, <string-name name-style="western"><surname>McKay</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>YSD</given-names></string-name>, <etal/><year>2016</year><article-title>A GWAS meta-analysis and replication study identifies a novel locus within <italic toggle="yes">CLPTM1L/TERT</italic> associated with nasopharyngeal carcinoma in individuals of Chinese ancestry</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source><volume>25</volume>: <fpage>188</fpage>–<lpage>192</lpage>.<pub-id pub-id-type="pmid">26545403</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1055-9965.EPI-15-0144</pub-id><pub-id pub-id-type="pmcid">PMC4713263</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C4">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Bello</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Chou</surname><given-names>JF</given-names></string-name>, <string-name name-style="western"><surname>Panageas</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Brady</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Coit</surname><given-names>DG</given-names></string-name>, <string-name name-style="western"><surname>Carvajal</surname><given-names>RD</given-names></string-name>, <string-name name-style="western"><surname>Ariyan</surname><given-names>CE</given-names></string-name>. <year>2013</year><article-title>Prognosis of acral melanoma: a series of 281 patients</article-title>. <source>Ann Surg Oncol</source><volume>20</volume>: <fpage>3618</fpage>–<lpage>3625</lpage>.<pub-id pub-id-type="pmid">23838913</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1245/s10434-013-3089-0</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C5">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Berger</surname><given-names>MF</given-names></string-name>, <string-name name-style="western"><surname>Hodis</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Heffernan</surname><given-names>TP</given-names></string-name>, <string-name name-style="western"><surname>Deribe</surname><given-names>YL</given-names></string-name>, <string-name name-style="western"><surname>Lawrence</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Protopopov</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ivanova</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Watson</surname><given-names>IR</given-names></string-name>, <string-name name-style="western"><surname>Nickerson</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Ghosh</surname><given-names>P</given-names></string-name>, <etal/><year>2012</year><article-title>Melanoma genome sequencing reveals frequent <italic toggle="yes">PREX2</italic> mutations</article-title>. <source>Nature</source><volume>485</volume>: <fpage>502</fpage>–<lpage>506</lpage>.<pub-id pub-id-type="pmid">22622578</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature11071</pub-id><pub-id pub-id-type="pmcid">PMC3367798</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C6">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Bradford</surname><given-names>PT</given-names></string-name>, <string-name name-style="western"><surname>Goldstein</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>McMaster</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Tucker</surname><given-names>MA</given-names></string-name>. <year>2009</year><article-title>Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005</article-title>. <source>Arch Dermatol</source><volume>145</volume>: <fpage>427</fpage>–<lpage>434</lpage>.<pub-id pub-id-type="pmid">19380664</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archdermatol.2008.609</pub-id><pub-id pub-id-type="pmcid">PMC2735055</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C7">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Brash</surname><given-names>DE</given-names></string-name>. <year>2015</year><article-title>UV signature mutations</article-title>. <source>Photochem Photobiol</source><volume>91</volume>: <fpage>15</fpage>–<lpage>26</lpage>.<pub-id pub-id-type="pmid">25354245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/php.12377</pub-id><pub-id pub-id-type="pmcid">PMC4294947</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C8">
          <mixed-citation publication-type="journal"><collab>The Cancer Genome Atlas Network</collab>. <year>2015</year><article-title>Genomic classification of cutaneous melanoma</article-title>. <source>Cell</source><volume>161</volume>: <fpage>1681</fpage>–<lpage>1696</lpage>.<pub-id pub-id-type="pmid">26091043</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2015.05.044</pub-id><pub-id pub-id-type="pmcid">PMC4580370</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C9">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Carvajal-Carmona</surname><given-names>LG</given-names></string-name>, <string-name name-style="western"><surname>O'Mara</surname><given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Painter</surname><given-names>JN</given-names></string-name>, <string-name name-style="western"><surname>Lose</surname><given-names>FA</given-names></string-name>, <string-name name-style="western"><surname>Dennis</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Michailidou</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Tyrer</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Ahmed</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ferguson</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Healey</surname><given-names>CS</given-names></string-name>, <etal/><year>2015</year><article-title>Candidate locus analysis of the <italic toggle="yes">TERT–CLPTM1L</italic> cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk</article-title>. <source>Hum Genet</source><volume>134</volume>: <fpage>231</fpage>–<lpage>245</lpage>.<pub-id pub-id-type="pmid">25487306</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00439-014-1515-4</pub-id><pub-id pub-id-type="pmcid">PMC4291520</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C10">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Chernoff</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Bordone</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Horst</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Simon</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Twadell</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Cohen</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Silvers</surname><given-names>DN</given-names></string-name>, <string-name name-style="western"><surname>Brunner</surname><given-names>G</given-names></string-name>, <etal/><year>2009</year><article-title><italic toggle="yes">GAB2</italic> amplifications refine molecular classification of melanoma</article-title>. <source>Clin Cancer Res</source><volume>15</volume>: <fpage>4288</fpage>–<lpage>4291</lpage>.<pub-id pub-id-type="pmid">19509136</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-09-0280</pub-id><pub-id pub-id-type="pmcid">PMC2878201</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C11">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Christoforides</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Carpten</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Weiss</surname><given-names>GJ</given-names></string-name>, <string-name name-style="western"><surname>Demeure</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Von Hoff</surname><given-names>DD</given-names></string-name>, <string-name name-style="western"><surname>Craig</surname><given-names>DW</given-names></string-name>. <year>2013</year><article-title>Identification of somatic mutations in cancer through Bayesian-based analysis of sequenced genome pairs</article-title>. <source>BMC Genomics</source><volume>14</volume>: <fpage>302</fpage>.<pub-id pub-id-type="pmid">23642077</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2164-14-302</pub-id><pub-id pub-id-type="pmcid">PMC3751438</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C12">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Cibulskis</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Lawrence</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Carter</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Sivachenko</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Jaffe</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Sougnez</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Gabriel</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Meyerson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lander</surname><given-names>ES</given-names></string-name>, <string-name name-style="western"><surname>Getz</surname><given-names>G</given-names></string-name>. <year>2013</year><article-title>Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples</article-title>. <source>Nat Biotechnol</source><volume>31</volume>: <fpage>213</fpage>–<lpage>219</lpage>.<pub-id pub-id-type="pmid">23396013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt.2514</pub-id><pub-id pub-id-type="pmcid">PMC3833702</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C13">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Curtin</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Fridlyand</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kageshita</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Patel</surname><given-names>HN</given-names></string-name>, <string-name name-style="western"><surname>Busam</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Kutzner</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname><given-names>KH</given-names></string-name>, <string-name name-style="western"><surname>Aiba</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Brocker</surname><given-names>EB</given-names></string-name>, <string-name name-style="western"><surname>LeBoit</surname><given-names>PE</given-names></string-name>, <etal/><year>2005</year><article-title>Distinct sets of genetic alterations in melanoma</article-title>. <source>N Engl J Med</source><volume>353</volume>: <fpage>2135</fpage>–<lpage>2147</lpage>.<pub-id pub-id-type="pmid">16291983</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa050092</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C14">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Curtin</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Busam</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Pinkel</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Bastian</surname><given-names>BC</given-names></string-name>. <year>2006</year><article-title>Somatic activation of KIT in distinct subtypes of melanoma</article-title>. <source>J Clin Oncol</source><volume>24</volume>: <fpage>4340</fpage>–<lpage>4346</lpage>.<pub-id pub-id-type="pmid">16908931</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2006.06.2984</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C15">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>de Lima Vazquez</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Vicente</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Carloni</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Berardinelli</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Soares</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Scapulatempo</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Martinho</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Reis</surname><given-names>RM</given-names></string-name>. <year>2016</year><article-title>Molecular profiling, including <italic toggle="yes">TERT</italic> promoter mutations, of acral lentiginous melanomas</article-title>. <source>Melanoma Res</source><volume>26</volume>: <fpage>93</fpage>–<lpage>99</lpage>.<pub-id pub-id-type="pmid">26709572</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CMR.0000000000000222</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C16">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Dobin</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Davis</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Schlesinger</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Drenkow</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zaleski</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Jha</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Batut</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Chaisson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gingeras</surname><given-names>TR</given-names></string-name>. <year>2013</year><article-title>STAR: ultrafast universal RNA-seq aligner</article-title>. <source>Bioinformatics</source><volume>29</volume>: <fpage>15</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="pmid">23104886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmcid">PMC3530905</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C17">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Furney</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Turajlic</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Stamp</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Thomas</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Hayes</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Strauss</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Gavrielides</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Xing</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Gore</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Larkin</surname><given-names>J</given-names></string-name>, <etal/><year>2014</year><article-title>The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis</article-title>. <source>Pigment Cell Melanoma Res</source><volume>27</volume>: <fpage>835</fpage>–<lpage>838</lpage>.<pub-id pub-id-type="pmid">24913711</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/pcmr.12279</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C18">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Griewank</surname><given-names>KG</given-names></string-name>, <string-name name-style="western"><surname>Murali</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Puig-Butille</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Schilling</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Livingstone</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Potrony</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Carrera</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Schimming</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Möller</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Schwamborn</surname><given-names>M</given-names></string-name>, <etal/><year>2014</year><article-title><italic toggle="yes">TERT</italic> promoter mutation status as an independent prognostic factor in cutaneous melanoma</article-title>. <source>J Natl Cancer Inst</source><volume>106</volume>: <fpage>dju246</fpage>.<pub-id pub-id-type="pmid">25217772</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/dju246</pub-id><pub-id pub-id-type="pmcid">PMC4200061</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C19">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Hodis</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Watson</surname><given-names>IR</given-names></string-name>, <string-name name-style="western"><surname>Kryukov</surname><given-names>GV</given-names></string-name>, <string-name name-style="western"><surname>Arold</surname><given-names>ST</given-names></string-name>, <string-name name-style="western"><surname>Imielinski</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Theurillat</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Nickerson</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Auclair</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Place</surname><given-names>C</given-names></string-name>, <etal/><year>2012</year><article-title>A landscape of driver mutations in melanoma</article-title>. <source>Cell</source><volume>150</volume>: <fpage>251</fpage>–<lpage>263</lpage>.<pub-id pub-id-type="pmid">22817889</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2012.06.024</pub-id><pub-id pub-id-type="pmcid">PMC3600117</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C20">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Horn</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Figl</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rachakonda</surname><given-names>PS</given-names></string-name>, <string-name name-style="western"><surname>Fischer</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Sucker</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gast</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kadel</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Moll</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Nagore</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Hemminki</surname><given-names>K</given-names></string-name>, <etal/><year>2013</year><article-title><italic toggle="yes">TERT</italic> promoter mutations in familial and sporadic melanoma</article-title>. <source>Science</source><volume>339</volume>: <fpage>959</fpage>–<lpage>961</lpage>.<pub-id pub-id-type="pmid">23348503</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1230062</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C21">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Huang</surname><given-names>FW</given-names></string-name>, <string-name name-style="western"><surname>Hodis</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Kryukov</surname><given-names>GV</given-names></string-name>, <string-name name-style="western"><surname>Chin</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Garraway</surname><given-names>LA</given-names></string-name>. <year>2013</year><article-title>Highly recurrent <italic toggle="yes">TERT</italic> promoter mutations in human melanoma</article-title>. <source>Science</source><volume>339</volume>: <fpage>957</fpage>–<lpage>959</lpage>.<pub-id pub-id-type="pmid">23348506</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1229259</pub-id><pub-id pub-id-type="pmcid">PMC4423787</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C22">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Hugo</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zaretsky</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Moreno</surname><given-names>BH</given-names></string-name>, <string-name name-style="western"><surname>Hu-Lieskovan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Berent-Maoz</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Pang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chmielowski</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Cherry</surname><given-names>G</given-names></string-name>. <year>2016</year><article-title>Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma</article-title>. <source>Cell</source><volume>165</volume>: <fpage>35</fpage>–<lpage>44</lpage>.<pub-id pub-id-type="pmid">26997480</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2016.02.065</pub-id><pub-id pub-id-type="pmcid">PMC4808437</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C23">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Johnson</surname><given-names>DB</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Abramson</surname><given-names>RG</given-names></string-name>, <string-name name-style="western"><surname>Ye</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wolchok</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Sosman</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Carvajal</surname><given-names>RD</given-names></string-name>, <string-name name-style="western"><surname>Ariyan</surname><given-names>CE</given-names></string-name>. <year>2015</year><article-title>Clinical activity of ipilimumab in acral melanoma: a retrospective review</article-title>. <source>Oncologist</source><volume>20</volume>: <fpage>648</fpage>–<lpage>652</lpage>.<pub-id pub-id-type="pmid">25964307</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1634/theoncologist.2014-0468</pub-id><pub-id pub-id-type="pmcid">PMC4571784</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C24">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kang</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Cui</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Scheid</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hendricks</surname><given-names>WP</given-names></string-name>, <string-name name-style="western"><surname>Schmidt</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sekulic</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kong</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Trent</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Gokhale</surname><given-names>V</given-names></string-name>, <etal/><year>2016</year><article-title>A pharmacological chaperone molecule induces cancer cell death by restoring tertiary DNA structures in mutant hTERT promoters</article-title>. <source>J Am Chem Soc</source><volume>5</volume>: <fpage>5</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jacs.6b07598</pub-id><pub-id pub-id-type="pmid">27643954</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C25">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Khan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>. <year>2016</year><article-title>dbSUPER: a database of super-enhancers in mouse and human genome</article-title>. <source>Nucleic Acids Res</source><volume>44</volume>: <fpage>D164</fpage>–<lpage>D171</lpage>.<pub-id pub-id-type="pmid">26438538</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkv1002</pub-id><pub-id pub-id-type="pmcid">PMC4702767</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C26">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kim</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Salzberg</surname><given-names>SL</given-names></string-name>. <year>2011</year><article-title>TopHat-Fusion: an algorithm for discovery of novel fusion transcripts</article-title>. <source>Genome Biol</source><volume>12</volume>: <fpage>R72</fpage>.<pub-id pub-id-type="pmid">21835007</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/gb-2011-12-8-r72</pub-id><pub-id pub-id-type="pmcid">PMC3245612</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C27">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kim</surname><given-names>NW</given-names></string-name>, <string-name name-style="western"><surname>Piatyszek</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Prowse</surname><given-names>KR</given-names></string-name>, <string-name name-style="western"><surname>Harley</surname><given-names>CB</given-names></string-name>, <string-name name-style="western"><surname>West</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Ho</surname><given-names>PL</given-names></string-name>, <string-name name-style="western"><surname>Coviello</surname><given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>Wright</surname><given-names>WE</given-names></string-name>, <string-name name-style="western"><surname>Weinrich</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Shay</surname><given-names>JW</given-names></string-name>. <year>1994</year><article-title>Specific association of human telomerase activity with immortal cells and cancer</article-title>. <source>Science</source><volume>266</volume>: <fpage>2011</fpage>–<lpage>2015</lpage>.<pub-id pub-id-type="pmid">7605428</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.7605428</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C28">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Krauthammer</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kong</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ha</surname><given-names>BH</given-names></string-name>, <string-name name-style="western"><surname>Evans</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bacchiocchi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>McCusker</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Davis</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Goh</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Choi</surname><given-names>M</given-names></string-name>, <etal/><year>2012</year><article-title>Exome sequencing identifies recurrent somatic <italic toggle="yes">RAC1</italic> mutations in melanoma</article-title>. <source>Nat Genet</source><volume>44</volume>: <fpage>1006</fpage>–<lpage>1014</lpage>.<pub-id pub-id-type="pmid">22842228</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.2359</pub-id><pub-id pub-id-type="pmcid">PMC3432702</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C29">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Law</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Montgomery</surname><given-names>GW</given-names></string-name>, <string-name name-style="western"><surname>Brown</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Martin</surname><given-names>NG</given-names></string-name>, <string-name name-style="western"><surname>Mann</surname><given-names>GJ</given-names></string-name>, <string-name name-style="western"><surname>Hayward</surname><given-names>NK</given-names></string-name>, <string-name name-style="western"><surname>MacGregor</surname><given-names>S</given-names></string-name>. <year>2012</year><article-title>Meta-analysis combining new and existing data sets confirms that the <italic toggle="yes">TERT–CLPTM1L</italic> locus influences melanoma risk</article-title>. <source>J Invest Dermatol</source><volume>132</volume>: <fpage>485</fpage>–<lpage>487</lpage>.<pub-id pub-id-type="pmid">21993562</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/jid.2011.322</pub-id><pub-id pub-id-type="pmcid">PMC3258346</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C30">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Durbin</surname><given-names>R</given-names></string-name>. <year>2009</year><article-title>Fast and accurate short read alignment with Burrows–Wheeler transform</article-title>. <source>Bioinformatics</source><volume>25</volume>: <fpage>1754</fpage>–<lpage>1760</lpage>.<pub-id pub-id-type="pmid">19451168</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btp324</pub-id><pub-id pub-id-type="pmcid">PMC2705234</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C31">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Liang</surname><given-names>WS</given-names></string-name>, <string-name name-style="western"><surname>Aldrich</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Tembe</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Kurdoglu</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Cherni</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Phillips</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Reiman</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Baker</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Weiss</surname><given-names>GJ</given-names></string-name>, <string-name name-style="western"><surname>Carpten</surname><given-names>JD</given-names></string-name>, <etal/><year>2014</year><article-title>Long insert whole genome sequencing for copy number variant and translocation detection</article-title>. <source>Nucleic Acids Res</source><volume>42</volume>: <fpage>e8</fpage>.<pub-id pub-id-type="pmid">24071583</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkt865</pub-id><pub-id pub-id-type="pmcid">PMC3902897</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C32">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Liau</surname><given-names>JY</given-names></string-name>, <string-name name-style="western"><surname>Tsai</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Jeng</surname><given-names>YM</given-names></string-name>, <string-name name-style="western"><surname>Chu</surname><given-names>CY</given-names></string-name>, <string-name name-style="western"><surname>Kuo</surname><given-names>KT</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>CW</given-names></string-name>. <year>2014</year><article-title><italic toggle="yes">TERT</italic> promoter mutation is uncommon in acral lentiginous melanoma</article-title>. <source>J Cutan Pathol</source><volume>41</volume>: <fpage>504</fpage>–<lpage>508</lpage>.<pub-id pub-id-type="pmid">24588324</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cup.12323</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C33">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Liu</surname><given-names>SG</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Cen</surname><given-names>QH</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>JX</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>JJ</given-names></string-name>. <year>2015</year><article-title>Association of genetic polymorphisms in <italic toggle="yes">TERT-CLPTM1L</italic> with lung cancer in a Chinese population</article-title>. <source>Genet Mol Res</source><volume>14</volume>: <fpage>4469</fpage>–<lpage>4476</lpage>.<pub-id pub-id-type="pmid">25966219</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4238/2015.May.4.4</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C34">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Love</surname><given-names>MI</given-names></string-name>, <string-name name-style="western"><surname>Huber</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Anders</surname><given-names>S</given-names></string-name>. <year>2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title>. <source>Genome Biol</source><volume>15</volume>: <fpage>550</fpage>.<pub-id pub-id-type="pmid">25516281</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmcid">PMC4302049</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C35">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Ong</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Jubb</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Jakubiak</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Rudolph</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Haverty</surname><given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Kowanetz</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Tremayne</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lisle</surname><given-names>R</given-names></string-name>, <etal/><year>2013</year><article-title>P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma</article-title>. <source>J Natl Cancer Inst</source><volume>105</volume>: <fpage>606</fpage>–<lpage>607</lpage>.<pub-id pub-id-type="pmid">23535073</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djt054</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C36">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Radu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Semenova</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Kosoff</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Chernoff</surname><given-names>J</given-names></string-name>. <year>2014</year><article-title>PAK signalling during the development and progression of cancer</article-title>. <source>Nat Rev Cancer</source><volume>14</volume>: <fpage>13</fpage>–<lpage>25</lpage>.<pub-id pub-id-type="pmid">24505617</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc3645</pub-id><pub-id pub-id-type="pmcid">PMC4115244</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C37">
          <mixed-citation publication-type="book"><string-name name-style="western"><surname>Reed</surname><given-names>R</given-names></string-name>, ed. <year>1976</year><source>New concepts in surgical pathology of the skin</source>. <publisher-name>John Wiley</publisher-name>, <publisher-loc>New York</publisher-loc>.</mixed-citation>
        </ref>
        <ref id="LIANGGR213348C38">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Saunders</surname><given-names>CT</given-names></string-name>, <string-name name-style="western"><surname>Wong</surname><given-names>WS</given-names></string-name>, <string-name name-style="western"><surname>Swamy</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Becq</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Murray</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>Cheetham</surname><given-names>RK</given-names></string-name>. <year>2012</year><article-title>Strelka: accurate somatic small-variant calling from sequenced tumor–normal sample pairs</article-title>. <source>Bioinformatics</source><volume>28</volume>: <fpage>1811</fpage>–<lpage>1817</lpage>.<pub-id pub-id-type="pmid">22581179</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/bts271</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C39">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Sauter</surname><given-names>ER</given-names></string-name>, <string-name name-style="western"><surname>Yeo</surname><given-names>UC</given-names></string-name>, <string-name name-style="western"><surname>von Stemm</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Litwin</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Tichansky</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Pistritto</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Nesbit</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pinkel</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Herlyn</surname><given-names>M</given-names></string-name>, <etal/><year>2002</year><article-title>Cyclin D1 is a candidate oncogene in cutaneous melanoma</article-title>. <source>Cancer Res</source><volume>62</volume>: <fpage>3200</fpage>–<lpage>3206</lpage>.<pub-id pub-id-type="pmid">12036934</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C40">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Shay</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Bacchetti</surname><given-names>S</given-names></string-name>. <year>1997</year><article-title>A survey of telomerase activity in human cancer</article-title>. <source>Eur J Cancer</source><volume>33</volume>: <fpage>787</fpage>–<lpage>791</lpage>.<pub-id pub-id-type="pmid">9282118</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0959-8049(97)00062-2</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C41">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Snyder</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Makarov</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Merghoub</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zaretsky</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Desrichard</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Walsh</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Postow</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Wong</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Ho</surname><given-names>TS</given-names></string-name>. <year>2014</year><article-title>Genetic basis for clinical response to CTLA-4 blockade in melanoma</article-title>. <source>N Engl J Med</source><volume>371</volume>: <fpage>2189</fpage>–<lpage>2199</lpage>.<pub-id pub-id-type="pmid">25409260</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1406498</pub-id><pub-id pub-id-type="pmcid">PMC4315319</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C42">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Trapnell</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Pertea</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Mortazavi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kwan</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>van Baren</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Salzberg</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Wold</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Pachter</surname><given-names>L</given-names></string-name>. <year>2010</year><article-title>Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation</article-title>. <source>Nat Biotechnol</source><volume>28</volume>: <fpage>511</fpage>–<lpage>515</lpage>.<pub-id pub-id-type="pmid">20436464</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt.1621</pub-id><pub-id pub-id-type="pmcid">PMC3146043</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C43">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Trapnell</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hendrickson</surname><given-names>DG</given-names></string-name>, <string-name name-style="western"><surname>Sauvageau</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Goff</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Rinn</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Pachter</surname><given-names>L</given-names></string-name>. <year>2013</year><article-title>Differential analysis of gene regulation at transcript resolution with RNA-seq</article-title>. <source>Nat Biotechnol</source><volume>31</volume>: <fpage>46</fpage>–<lpage>53</lpage>.<pub-id pub-id-type="pmid">23222703</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt.2450</pub-id><pub-id pub-id-type="pmcid">PMC3869392</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C44">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Turajlic</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Furney</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Lambros</surname><given-names>MB</given-names></string-name>, <string-name name-style="western"><surname>Mitsopoulos</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kozarewa</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Geyer</surname><given-names>FC</given-names></string-name>, <string-name name-style="western"><surname>Mackay</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hakas</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zvelebil</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lord</surname><given-names>CJ</given-names></string-name>, <etal/><year>2012</year><article-title>Whole genome sequencing of matched primary and metastatic acral melanomas</article-title>. <source>Genome Res</source><volume>22</volume>: <fpage>196</fpage>–<lpage>207</lpage>.<pub-id pub-id-type="pmid">22183965</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/gr.125591.111</pub-id><pub-id pub-id-type="pmcid">PMC3266028</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C45">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Van Allen</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Miao</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Schilling</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Shukla</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Blank</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zimmer</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Sucker</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hillen</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Foppen</surname><given-names>MHG</given-names></string-name>, <string-name name-style="western"><surname>Goldinger</surname><given-names>SM</given-names></string-name>. <year>2015</year><article-title>Genomic correlates of response to CTLA-4 blockade in metastatic melanoma</article-title>. <source>Science</source><volume>350</volume>: <fpage>207</fpage>–<lpage>211</lpage>.<pub-id pub-id-type="pmid">26359337</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aad0095</pub-id><pub-id pub-id-type="pmcid">PMC5054517</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C47">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Wei</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Shang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Su</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>H</given-names></string-name>, <etal/><year>2016</year><article-title>SEA: a super-enhancer archive</article-title>. <source>Nucleic Acids Res</source><volume>44</volume>: <fpage>D172</fpage>–<lpage>D179</lpage>.<pub-id pub-id-type="pmid">26578594</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkv1243</pub-id><pub-id pub-id-type="pmcid">PMC4702879</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C48">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Yi</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Shay</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Wright</surname><given-names>WE</given-names></string-name>. <year>2001</year><article-title>Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells</article-title>. <source>Nucleic Acids Res</source><volume>29</volume>: <fpage>4818</fpage>–<lpage>4825</lpage>.<pub-id pub-id-type="pmid">11726691</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/29.23.4818</pub-id><pub-id pub-id-type="pmcid">PMC96692</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C49">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Zhang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Bu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Dai</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>C</given-names></string-name>. <year>2015</year><article-title>Genetic variations in the TERT and CLPTM1L gene region and gastrointestinal stromal tumors risk</article-title>. <source>Oncotarget</source><volume>6</volume>: <fpage>31360</fpage>–<lpage>31367</lpage>.<pub-id pub-id-type="pmid">26372813</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.5153</pub-id><pub-id pub-id-type="pmcid">PMC4741611</pub-id></mixed-citation>
        </ref>
        <ref id="LIANGGR213348C50">
          <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Zhang</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Dutton-Regester</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Brown</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Hayward</surname><given-names>NK</given-names></string-name>. <year>2016</year><article-title>The genomic landscape of cutaneous melanoma</article-title>. <source>Pigment Cell Melanoma Res</source><volume>29</volume>: <fpage>266</fpage>–<lpage>283</lpage>.<pub-id pub-id-type="pmid">26833684</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/pcmr.12459</pub-id></mixed-citation>
        </ref>
      </ref-list>
    </back>
  </article>
</pmc-articleset>
